非心脏手术患者围术期口服抗血栓药物治疗管理  

Perioperative oral antithrombotic drugs therapy management in non-cardiac surgery patients

作　　者：任爽 武丹威 韩爽 甄健存 张威 Ren Shuang;Wu Danwei;Han Shuang;Zhen Jiancun;Zhang Wei(Department of Pharmacy,Beijing Jishuitan Hospital,Capital Medical University,Beijing 100035,China)

机构地区：[1]首都医科大学附属北京积水潭医院药学部,北京100035

出　　处：《中国药物与临床》2025年第1期27-31,共5页Chinese Remedies & Clinics

基　　金：首都卫生发展科研专项(首发2024-2-2077);北京市属医院科研培育项目(PG2025005)。

摘　　要：血栓性疾病是心血管疾病中重要的一组疾病,药物治疗是该类疾病治疗的基本手段。对于术前长期口服抗凝药物或抗血小板药物的患者,围术期如继续服用可增加手术出血风险,而停用则可增加血栓栓塞的风险,应平衡手术出血和血栓栓塞风险。本研究结合国内外研究进展,在围术期血栓及出血风险评估,口服抗凝药物和抗血小板药物的治疗管理及桥接抗凝情况等予以说明,以期为上述药物在非心脏手术患者围术期的安全应用提供参考。Thrombotic diseases are an important group of cardiovascular diseases,and the antithrombotic drugs are the basic therapeutic treatment for such diseases.For patients who take antithrombotic drugs for a long time before surgery,continuing to take antithrombotic drugs during perioperative period may increase the risk of surgical bleeding,while discontinuing them may increase the risk of thromboembolism.The risk of surgical bleed-ing and thromboembolism should be balanced.Based on the research progress,this paper explains perioperative risk assessment of thrombosis and bleeding,therapy management of oral anticoagulants and antiplatelet drugs,and bridging anticoagulation,in order to provide reference for preoperative management of antithrombotic drugs in non-cardiac surgery patients.

关 键 词：抗凝药 血小板聚集抑制剂 围手术期 药物疗法管理 

分 类 号：R54[医药卫生—心血管疾病]